An update on outcomes for COPD pharmacological trials: a COPD investigators report-reassessment of the 2008 American Thoracic Society/European Respiratory …
M Cazzola, P Rogliani, PJ Barnes, F Blasi… - American Journal of …, 2023 - atsjournals.org
Background: In 2008, a dedicated American Thoracic Society/European Respiratory Society
task force published a paper on the possible use and limitations of clinical outcomes and …
task force published a paper on the possible use and limitations of clinical outcomes and …
The impact of impaired sleep quality on symptom change and future exacerbation of chronic obstructive pulmonary disease
L Lin, Q Song, J Duan, C Liu, W Cheng, A Zhou… - Respiratory …, 2023 - Springer
Purpose Study the impact of impaired sleep quality on symptom change and future
exacerbation of chronic obstructive pulmonary disease (COPD) patients. Methods This was …
exacerbation of chronic obstructive pulmonary disease (COPD) patients. Methods This was …
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?
EM Kerwin, PW Jones, LH Bjermer… - Chronic Respiratory …, 2023 - journals.sagepub.com
This review addresses outstanding questions regarding initial pharmacological
management of chronic obstructive pulmonary disease (COPD). Optimizing initial treatment …
management of chronic obstructive pulmonary disease (COPD). Optimizing initial treatment …
Real-world effectiveness of inhalation therapy among patients with symptomatic COPD in China: a multicenter prospective study
W Cheng, J Duan, A Zhou, Y Zhao, R Yi… - Frontiers in …, 2021 - frontiersin.org
Purpose: This real-world study evaluated the effectiveness of different inhalation therapies in
patients with symptomatic chronic obstructive pulmonary disease (COPD) in China and also …
patients with symptomatic chronic obstructive pulmonary disease (COPD) in China and also …
Tiotropium reduces clinically important deterioration in patients with mild-to-moderate chronic obstructive pulmonary disease: A post hoc analysis of the Tie-COPD …
F Wu, C Dai, Y Zhou, Z Deng, Z Wang, X Li, S Chen… - Respiratory …, 2024 - Elsevier
Background Clinically important deterioration (CID) is a composite endpoint used to
holistically assess the complex progression of chronic obstructive pulmonary disease …
holistically assess the complex progression of chronic obstructive pulmonary disease …
Comparation of predictive value of CAT and change in CAT in the short term for future exacerbation of chronic obstructive pulmonary disease
L Lin, Q Song, W Cheng, C Liu, YY Zhao… - Annals of …, 2022 - Taylor & Francis
Purpose Our study aimed to compare the predictive value of the COPD Assessment Test
(CAT) score at baseline and short-term change in CAT for future exacerbations in chronic …
(CAT) score at baseline and short-term change in CAT for future exacerbations in chronic …
Pharmacotherapy of LAMA/LABA inhaled therapy combinations for chronic obstructive pulmonary disease: a clinical overview
MG Matera, B Rinaldi, C Belardo… - Expert Review of Clinical …, 2022 - Taylor & Francis
Introduction Long-acting muscarinic receptor antagonist (LAMA)/β2-agonist (LABA)
combinations represent a significant improvement in the treatment of chronic obstructive …
combinations represent a significant improvement in the treatment of chronic obstructive …
[HTML][HTML] Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD
F Maltais, CF Vogelmeier, EM Kerwin, LH Bjermer… - Respiratory …, 2022 - Elsevier
Early MAXimisation of bronchodilation for improving COPD stability (EMAX) was a large,
multicentre, multi-national, randomised, double-blind, 24-week trial. EMAX evaluated the …
multicentre, multi-national, randomised, double-blind, 24-week trial. EMAX evaluated the …